Evidence map›Paper›PMID 41553700›Full record

ArticleDermatology and therapy2026

Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study.

Jonathan I Silverberg, Lindsay Ackerman, Jerry Bagel, Linda Stein Gold, Andrew Blauvelt, David Rosmarin, Raj Chovatiya, Matthew Zirwas, Gil Yosipovitch, Jill Waibel and 14 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05369403 (An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05369403 phase3completednot on this map

An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

TypeinterventionalSponsorEli Lilly and CompanyRan2022 to 2025Enrolled86ConditionsAtopic DermatitisArmsLebrikizumab
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Jonathan I SilverbergGeorge Washington University School of Medicine and Health Sciences, 2150 Pennsylvania Ave NW 2Nd Floor, Washington, DC, 20037, USA. jonathanisilverberg@gmail.com.
Lindsay AckermanU.S. Dermatology Partners, Phoenix, AZ, USA.
Jerry BagelEczema Treatment Center of Central New Jersey, East Windsor, NJ, USA.
Linda Stein GoldDepartment of Dermatology, Henry Ford Hospital, Detroit, MI, USA.
Andrew BlauveltBlauvelt Consulting, LLC, Annapolis, MD, USA.
David RosmarinIndiana University School of Medicine, Indianapolis, IN, USA.
Raj ChovatiyaChicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.
Matthew ZirwasDOCS Dermatology, Baxley, OH, USA.
Gil YosipovitchUniversity of Miami Miller School of Medicine, Miami, FL, USA.
Jill WaibelMiami Dermatology and Laser Institute, Miami, FL, USA.
Jenny E MuraseUniversity of California, San Francisco, CA, USA.
Ben LockshinDermAssociates, Silver Spring, MD, USA.
Jamie WeismanMedical Dermatology Specialists, Atlanta, GA, USA.
Amber Reck AtwaterEli Lilly and Company, Indianapolis, IN, USA.
Jennifer ProperEli Lilly and Company, Indianapolis, IN, USA.
Maria SilkEli Lilly and Company, Indianapolis, IN, USA.
Evangeline PierceEli Lilly and Company, Indianapolis, IN, USA.
Maria Lucia Buziqui PiruzeliEli Lilly and Company, Indianapolis, IN, USA.
Sonia MontmayeurEli Lilly and Company, Indianapolis, IN, USA.
Christopher SchusterEli Lilly and Company, Indianapolis, IN, USA.
Jinglin ZhongIQVIA, Durham, NC, USA.
Maria Jose RuedaEli Lilly and Company, Indianapolis, IN, USA.
Sreekumar PillaiEli Lilly and Company, Indianapolis, IN, USA.
Eric SimpsonOregon Health & Science University, Portland, OR, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab need additional therapeutic options. Lebrikizumab's distinct mechanism of action may provide that alternative treatment. We evaluated efficacy and safety of lebrikizumab in adults and adolescents with moderate-to-severe AD previously treated with dupilumab.

methodsIn the open-label ADapt trial, patients who discontinued dupilumab due to inadequate response, adverse events (AEs)/intolerance, or other reasons received lebrikizumab 250-mg every 2 weeks (Q2W) following 500-mg loading dose at baseline/week 2, through week 16, with optional topical therapy. From weeks 16-24, responders (≥ 75% improvement in Eczema Area and Severity Index [EASI 75] or Investigator's Global Assessment score 0/1 with ≥ 2-point improvement from baseline) received lebrikizumab every 4 weeks; inadequate responders continued lebrikizumab Q2W. The primary endpoint was EASI 75 at week 16 in the intent-to-treat population; EASI 75 was also analyzed by reason for dupilumab discontinuation. Secondary and exploratory efficacy endpoints were assessed throughout.

resultsAmong the 86 patients enrolled, primary reasons for stopping dupilumab were inadequate response (n = 48, 55.8%), AEs/intolerance (n = 14, 16.3%), and other reasons (n = 24, 27.9%). Fifty-nine patients (68.6%) completed week 16; 52 patients (60.5%) completed week 24. At weeks 16 and 24, respectively, response rates were 57.4% (35/61) and 60.0% (33/55) for EASI 75; 53.2% (25/47) and 61.5% (24/39) for Pruritus Numeric Rating Scale ≥ 4-point improvement; and 83.0% (44/53) and 83.0% (39/47) for Dermatology Life Quality Index ≥ 4-point improvement. Most treatment-emergent AEs were mild/moderate. Serious AEs and discontinuations due to AEs were reported by 2 (2.3%) and 5 (5.8%) patients, respectively. Of the 10 patients who discontinued dupilumab due to eye-related events, facial dermatitis, or inflammatory arthritis, none reported similar events with lebrikizumab.

conclusionResults suggest that lebrikizumab provides meaningful improvements in skin clearance, itch, and quality of life in dupilumab-experienced patients with moderate-to-severe AD, with a safety profile consistent with other lebrikizumab phase 3 trials.

trial registrationClinicalTrials.gov identifier, NCT05369403.

Indexed as

Atopic dermatitisDupilumab-experiencedItch reliefLebrikizumabSkin clearance

Identifiers

PMID41553700
PMCPMC12936214

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.